Enzon Inc. (NASDAQ:ENZN) of Piscataway, N.J., and CreativeBioMolecules of Hopkinton, Mass., have signed a letter of intentto negotiate a definitive collaborative agreement for Enzon'ssingle-chain antigen-binding protein technology and CBM'sbiosynthetic antibody binding site protein technology.
In September, the U.S. Court of Appeals decided in favor ofEnzon in an appeal filed by CBM of a June 1991 decision by theU.S. Patent and Trademark Office terminating CBM'sinterference proceedings against Enzon's primary SCA patent.
(c) 1997 American Health Consultants. All rights reserved.